MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year. … [Read more…]
A patented dietary supplement clinically shown to alleviate occasional gastrointestinal side effects BOULDER, Colo.–(BUSINESS WIRE)–Starting today, Relesium™, a new gut-health solution for GLP-1 users, is available as an all-natural dietary supplement designed to alleviate occasional gastrointestinal (GI) issues and support gut health. With its patented formula, Relesium offers a targeted, safe, and clinically backed solution … [Read more…]
– Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases … [Read more…]
PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns. Data reinforces how increased coverage, decreased cost, and acceptability can be achieved with vaccines administered with the Tropis® ID System, the first and only needle-free ID delivery technology to achieve WHO prequalification. GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet®, a … [Read more…]
Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab) in the EU market European Commission approval based on totality of evidence including extensive comparative analytical, pharmacokinetic and clinical data The company expands its biosimilar portfolio to 11 in 2025 as planned, further strengthening its … [Read more…]
Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experience to Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the … [Read more…]
HALIFAX-KJIPUKTUK, Nova Scotia–(BUSINESS WIRE)–CUPE Nova Scotia is once again disappointed to see the Houston government prioritize private profits while leaving the struggling public services behind. “This has become the status quo,” said CUPE Nova Scotia President Nan McFadgen. “The conservative government promises to spend millions of dollars fixing health care, fixing housing, fixing the concerns … [Read more…]
WINNIPEG, Manitoba–(BUSINESS WIRE)–The Bioscience Association Manitoba (BAM) is thrilled to announce its annual Industry Celebration Dinner, set to take place on March 12, 2025. This highly anticipated event brings together leaders, innovators, educators, and future visionaries to celebrate the achievements within Manitoba’s thriving bioscience sector. As part of the evenings program, we are proud to … [Read more…]
Pompeian Olive Oil: Endorsed by the American Heart Association as a Heart-Healthy Choice BALTIMORE–(BUSINESS WIRE)–This Heart Health Month, leading nutritionist and researcher Dr. Nicole Avena encourages everyone to take a simple, science-backed step toward better health: replace butter with heart-healthy olive oil in your daily meals. Small changes in the kitchen can yield significant benefits … [Read more…]
Gilead Sciences’ window to exercise its option to casdatifan has expired; $150 million financing enables Arcus to independently advance its development program for casdatifan New data from the ARC-20 study in patients with clear cell renal cell carcinoma (ccRCC) showed that casdatifan monotherapy demonstrated improvements in the rate of primary progression, overall response rate (ORR) … [Read more…]
